Dyskinesia is a condition that causes involuntary, unpredictable movements that people cannot control. These movements often appear as writhing, jerking, or dance-like motions affecting the face, arms, legs, or trunk. While dyskinesia itself is not a disease, it most commonly occurs as a side effect of medications used to treat other conditions, particularly Parkinson’s disease.

Understanding Dyskinesia

Dyskinesia refers to involuntary, erratic movements that can affect different parts of the body. The word comes from medical terminology where “dys” means abnormal and “kinesia” refers to movement. These movements are often fluid and dance-like in appearance, though they can also manifest as rapid jerking motions or slow, extended muscle contractions that cause twisting.^[1]

What makes dyskinesia particularly challenging is that these movements are completely involuntary, meaning the person experiencing them has no control over when they start or stop. The movements can range from very subtle motions that barely attract notice to severe symptoms that significantly interfere with daily activities and social interactions.^[7]

It’s important to understand that dyskinesia is not a symptom of the underlying disease itself, such as Parkinson’s disease. Rather, it represents a complication that emerges from treatment, specifically from medications designed to help manage the original condition. This distinction matters because it affects how doctors approach management and what patients can expect from their treatment journey.^[1]

Causes of Dyskinesia

The primary cause of dyskinesia relates to long-term use of certain medications, particularly those that affect dopamine, a chemical messenger in the brain that helps control movement. Dopamine plays a crucial role in how our brain coordinates smooth, controlled movements. When this system gets disrupted, either by disease or medication, involuntary movements can emerge.^[7]

In people with Parkinson’s disease, the most common scenario involves a medication called levodopa. This drug is the most frequently prescribed treatment for Parkinson’s disease because it temporarily restores dopamine levels in the brain. However, levodopa needs to be taken multiple times throughout the day because it wears off relatively quickly. This creates a situation where dopamine levels in the body rise and fall repeatedly, rather than remaining steady. These fluctuating levels, combined with the continued loss of dopamine-producing brain cells that occurs in Parkinson’s, make it impossible to maintain stable dopamine, which contributes to the development of dyskinesia.^[11]

Scientists believe several brain chemicals beyond dopamine may play a role in dyskinesia development. These include serotonin, which affects mood and behavior, glutamate, which sends signals between nerve cells, and a chemical called GABA. The interaction between these different chemical messengers in the brain is complex. Some researchers think that when brain cells become super-sensitive to dopamine after long periods of low levels, they may flood the system with too much GABA when levodopa is taken, potentially triggering dyskinesia.^[7]

Another form of dyskinesia, called tardive dyskinesia, develops from a different class of medications altogether. This type occurs after exposure to drugs that block dopamine receptors, with the majority being antipsychotic medications used to treat conditions like schizophrenia. Tardive dyskinesia can also result from certain antidepressants, medications for high blood pressure, antihistamines, or drugs used to prevent nausea.^[10]

Risk Factors

Several factors can increase a person’s likelihood of developing dyskinesia when taking medications that affect dopamine. Understanding these risk factors helps patients and doctors make more informed decisions about treatment approaches.^[7]

Age at the time of diagnosis plays a significant role. Younger people with Parkinson’s disease, particularly those diagnosed before age 40, are thought to develop dyskinesia earlier in their treatment journey compared to those diagnosed later in life. This happens even though younger patients may be taking the same medications at similar doses. The reason for this age-related difference is not fully understood, but it appears to relate to how younger brains respond to levodopa treatment.^[1]

The duration of levodopa treatment matters considerably. Most people don’t develop dyskinesia immediately when they start taking levodopa. Instead, it typically begins after several years of treatment, often appearing after someone has been taking the medication for five to ten years. The longer a person continues treatment with levodopa, the higher their risk becomes.^[7]

The dose and frequency of medication also influence risk. Taking higher doses of levodopa or taking it very frequently throughout the day increases the likelihood of developing dyskinesia. This creates a challenging balance for doctors and patients because higher doses often provide better control of Parkinson’s symptoms, but they also carry greater risk of this complication.^[7]

The specific type of Parkinson’s disease a person has can affect their risk level. People with the akinetic-rigid type of Parkinson’s, where movements are stiff and slow but tremors may be absent, have a higher likelihood of developing dyskinesia. In contrast, those who experience tremors as their primary symptom tend to have lower risk.^[7]

Stress levels can influence both the development and severity of dyskinesia. People who experience high levels of ongoing stress may find their risk increases or their symptoms worsen. Any type of stress—whether physical, medical, surgical, or psychological—can aggravate dyskinesia and make the involuntary movements more pronounced.^[12]

Research suggests that about half of all people taking levodopa eventually develop some form of dyskinesia. However, this also means that half do not, even with long-term use of the medication. Individual variation in response to treatment remains an important factor that scientists continue to study.^[7]

Symptoms and How They Affect Daily Life

The appearance and impact of dyskinesia varies considerably from person to person. For some individuals, the movements are so mild they barely notice them, while for others, the symptoms can significantly disrupt daily activities and quality of life.^[1]

Common manifestations include writhing movements of the face, where the facial muscles move involuntarily in fluid, continuous patterns. The mouth and tongue are frequently affected, with symptoms such as lip-smacking, tongue protrusion where the tongue pushes forward out of the mouth, or the tongue moving around inside the mouth and pushing against the cheeks. Grimacing, where the face contorts into expressions the person doesn’t intend to make, also occurs frequently.^[16]

The arms and legs often show jerking motions or slow, extended movements. Fingers may move repetitively without the person’s intention. The trunk can sway or twist. These movements tend to be fluid and dance-like rather than the rigid, stiff movements associated with Parkinson’s disease itself. Head bobbing, where the head moves forward and backward or side to side, can also occur.^[11]

An interesting characteristic of dyskinesia is when it typically appears during the day. Most commonly, these involuntary movements occur during what doctors call the “on” period—the time when Parkinson’s medications are working best to control the disease’s primary symptoms like slowness, stiffness, and tremors. This creates a complex situation where the medication that provides the most relief from Parkinson’s symptoms also causes the unwanted extra movements.^[11]

Dyskinesia usually starts on the same side of the body where Parkinson’s symptoms first appeared. Initially, the movements may be so subtle that the person experiencing them doesn’t even notice. Family members or friends might be the first to observe these extra movements. Over time, as the condition progresses, the movements can become more noticeable and potentially spread to other parts of the body.^[7]

The emotional and social impact of dyskinesia can be substantial. Some people become self-conscious about their involuntary movements, worrying that others are watching or judging them. This self-consciousness can lead to social withdrawal or anxiety, particularly in crowded places or during important social interactions. The fear of experiencing noticeable movements in public can affect a person’s willingness to participate in social activities, attend events, or even go shopping.^[15]

Stress and excitement tend to make dyskinesia worse. When someone feels anxious or emotionally activated, the involuntary movements often become more pronounced and harder to ignore. This creates a difficult cycle where anxiety about the movements makes them worse, which in turn increases anxiety.^[11]

Despite these challenges, many people with Parkinson’s disease report that they prefer having some dyskinesia if it means their primary Parkinson’s symptoms remain well controlled. They would rather experience involuntary movements than return to the stiffness, slowness, and inability to move that characterize poorly controlled Parkinson’s. However, for others, particularly when dyskinesia becomes severe, the involuntary movements themselves can interfere with normal functioning, become painful, or significantly disrupt exercise and daily activities.^[1]

Different Types of Dyskinesia

Medical professionals recognize several distinct patterns of dyskinesia based on when the movements occur in relation to medication timing. Understanding these patterns helps doctors adjust treatment more effectively.^[1]

Peak dose dyskinesia is the most common form. As the name suggests, these movements occur when the concentration of levodopa in the bloodstream reaches its highest point, typically one to two hours after taking the medication. This timing usually coincides with when the medication is working best to control the motor symptoms of Parkinson’s disease. In the earliest stages, peak dose dyskinesia is often mild and may not bother the person experiencing it.^[1]

Diphasic dyskinesia follows a different pattern. Instead of occurring at peak medication levels, these movements happen during two specific times: when someone is just beginning their “on” period as the medication starts working, and again when they begin to turn “off” as the medication wears off. This pattern is sometimes called the dyskinesia-improvement-dyskinesia syndrome, or D-I-D syndrome, because the movements appear, disappear while the medication is working optimally, then reappear as medication effects decline.^[1]

Tardive dystonia represents a subtype that causes muscles which normally work together in a complementary way to fight against each other instead. This results in body parts twisting into abnormal postures or adopting unusual positions. Unlike the fluid, dance-like movements of typical dyskinesia, tardive dystonia involves more sustained muscle contractions that can be quite uncomfortable.^[12]

Prevention Strategies

While there’s no guaranteed way to prevent dyskinesia entirely, several approaches can potentially reduce risk or delay its onset for people who need to take medications that affect dopamine.^[11]

Starting with the lowest effective dose of levodopa and increasing it gradually only when necessary can help minimize risk. Doctors now understand that using the minimum dose needed to control symptoms, rather than immediately jumping to higher doses, may help delay the onset of dyskinesia. This requires careful monitoring and frequent communication between patients and their healthcare providers to find the sweet spot where symptoms are controlled without using unnecessarily high doses.^[11]

Some doctors consider starting newly diagnosed Parkinson’s patients on medications other than levodopa initially, reserving levodopa for when it becomes truly necessary. This strategy, sometimes used particularly with younger patients who face higher dyskinesia risk, aims to delay exposure to levodopa and potentially postpone the development of movement complications.^[11]

Extended-release formulations of levodopa, such as a medication called Rytary, or continuous infusion methods may help maintain more stable dopamine levels throughout the day. By reducing the peaks and valleys in medication levels that occur with immediate-release formulations taken multiple times daily, these delivery methods might decrease dyskinesia risk or severity.^[11]

For people at risk of tardive dyskinesia from antipsychotic medications, informed consent and regular monitoring are essential prevention strategies. Before starting treatment with dopamine-blocking drugs, healthcare providers should discuss the risk of tardive dyskinesia with patients. Regular reassessment of whether the medication remains necessary, and whether lower doses might be effective, helps minimize exposure. Some newer atypical antipsychotic medications appear to carry lower risk compared to older medications.^[10]

Stress management plays an important role in prevention and management. Since stress can worsen dyskinesia, developing healthy coping strategies—such as meditation, deep breathing exercises, regular physical activity, and maintaining a consistent daily routine—may help reduce symptom severity. Creating a comfortable, low-stress environment whenever possible can make a meaningful difference.^[12]

Maintaining overall health through a balanced diet rich in fruits, vegetables, and whole grains supports general wellbeing. Regular exercise, particularly low-impact activities like yoga, swimming, or walking, benefits both the underlying condition and potentially helps with dyskinesia management. Quality sleep also plays a crucial role in how the body responds to medications and manages stress.^[13]

How Dyskinesia Changes Body Function

Understanding what happens in the body during dyskinesia helps explain why these involuntary movements occur and why they can be so difficult to control. The pathophysiology, or the changes in normal body function that occur with disease, involves complex interactions between brain chemicals, nerve cells, and movement control systems.^[7]

In a healthy brain, dopamine-producing cells in a region called the substantia nigra send signals that help control smooth, coordinated movements. These cells release dopamine in a steady, regulated manner that allows the brain’s movement control centers to function properly. When Parkinson’s disease develops, these dopamine-producing cells gradually die off, creating a shortage of dopamine that leads to the characteristic slowness, stiffness, and tremor of the disease.^[11]

Levodopa treatment attempts to compensate for this loss by providing the brain with a substance it can convert into dopamine. When someone takes levodopa, it crosses from the bloodstream into the brain where remaining cells convert it to dopamine. Initially, when more dopamine-producing cells remain intact, these cells can store excess levodopa-derived dopamine and release it gradually, maintaining relatively stable levels. This storage capacity acts as a buffer, smoothing out the peaks and valleys that occur with intermittent medication doses.^[7]

However, as Parkinson’s progresses and more dopamine-producing cells die, this storage capacity disappears. Without enough cells to store and gradually release dopamine, levels in the brain begin to fluctuate dramatically based directly on when medication is taken. After each dose, dopamine levels spike high, then drop rapidly as the medication wears off. These dramatic swings, repeated multiple times daily over months and years, fundamentally alter how the brain’s movement control systems respond.^[7]

The cells that receive dopamine signals become hypersensitive to these fluctuating levels. When dopamine is present at high concentrations after taking levodopa, these sensitized cells may overreact, sending excessive signals that result in the involuntary movements of dyskinesia. Some researchers believe this oversensitivity involves changes in how cells respond not just to dopamine itself, but to other neurotransmitters including serotonin and glutamate.^[7]

The GABA system provides another piece of the pathophysiology puzzle. Dopamine signals get passed along through a chain of cells, with some cells using GABA to relay messages onward. During the long period when dopamine levels are low in untreated Parkinson’s, these GABA-producing cells receive fewer dopamine signals and may become extremely sensitive. When levodopa suddenly floods the system with dopamine, these sensitized cells might release excessive amounts of GABA, contributing to the abnormal movement patterns of dyskinesia.^[7]

In tardive dyskinesia caused by dopamine-blocking medications, the mechanism differs somewhat. These medications prevent dopamine from binding to its receptors on receiving cells. Over time, the blocked cells may become supersensitive, producing more receptors or making existing receptors more responsive in an attempt to compensate for the blockade. When the medication is reduced or stopped, this supersensitivity can result in excessive dopamine signaling and involuntary movements.^[10]

Oxidative stress, which occurs when harmful molecules called free radicals damage cells, may also contribute to dyskinesia development. The chemical reactions involved in dopamine production and breakdown naturally create some free radicals. When these processes become disrupted by medication and disease, increased oxidative stress might damage the delicate neural circuits controlling movement, making dyskinesia more likely.^[10]